Perspective Therapeutics (NYSE:CATX) Price Target Cut to $15.00 by Analysts at Royal Bank of Canada

Perspective Therapeutics (NYSE:CATX - Free Report) had its target price reduced by Royal Bank of Canada from $16.00 to $15.00 in a research note released on Thursday morning,Benzinga reports. They currently have an outperform rating on the stock.

Several other research analysts have also recently issued reports on the company. HC Wainwright reissued a "buy" rating and issued a $10.00 target price on shares of Perspective Therapeutics in a research report on Wednesday, March 19th. Cantor Fitzgerald upgraded shares of Perspective Therapeutics to a "strong-buy" rating in a research report on Tuesday, March 4th. Brookline Capital Management upgraded shares of Perspective Therapeutics to a "strong-buy" rating in a research report on Monday, March 10th. Wedbush restated an "outperform" rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a research note on Wednesday, March 26th. Finally, Scotiabank started coverage on Perspective Therapeutics in a research report on Friday, March 7th. They set a "sector outperform" rating and a $15.00 target price on the stock. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $14.44.

Perspective Therapeutics Trading Down 1.6 %

NYSE:CATX traded down $0.04 during trading hours on Thursday, reaching $2.17. The company had a trading volume of 439,246 shares, compared to its average volume of 997,898. The firm's 50 day moving average price is $2.94 and its 200-day moving average price is $6.29. Perspective Therapeutics has a 52 week low of $2.02 and a 52 week high of $19.05.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Y Intercept Hong Kong Ltd purchased a new stake in Perspective Therapeutics during the fourth quarter valued at $33,000. Aigen Investment Management LP purchased a new stake in shares of Perspective Therapeutics during the 4th quarter valued at about $34,000. National Bank of Canada FI lifted its holdings in shares of Perspective Therapeutics by 549,900.0% in the 4th quarter. National Bank of Canada FI now owns 11,000 shares of the company's stock valued at $35,000 after acquiring an additional 10,998 shares during the last quarter. ProShare Advisors LLC grew its position in Perspective Therapeutics by 49.1% in the fourth quarter. ProShare Advisors LLC now owns 15,225 shares of the company's stock worth $49,000 after acquiring an additional 5,011 shares in the last quarter. Finally, Vontobel Holding Ltd. bought a new stake in Perspective Therapeutics during the fourth quarter worth approximately $51,000. 54.66% of the stock is currently owned by institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.